”Approaching the end of the pandemic is a relief on a human level, far beyond business life. However, it is fair to say that wearing the Episurf jersey during the pandemic has been extremely tough. Elective surgery has been severely hit, with experimental elective surgery even more so. Hence, that we have been able to deliver growth throughout the pandemic, and that we now, finally, are expecting a return to normalcy, is just highly encouraging. We are in a better position than ever, with a strengthened organisation, several products in the pipeline, a strong scientific foundation to operate from, regulatory access to several markets globally, and a strong financial position. We are very optimistic about the future, and although Q1 2022 still offers some COVID-related challenges, we expect to take significant steps during 2022”, says Pål Ryfors, CEO Episurf Medical.
Fourth quarter 2021 compared to 2020, Group
- Gross order intake amounted to SEK 1.6m (1.3), an increase of 23%
- Order book amounted to SEK 1.3m (1.3)
- Group net sales amounted to SEK 1.5m (1.5)
- Loss for the period amounted to SEK -18.9m (-16.2)
- Earnings per share amounted to SEK -0.08 (-0.08)
Twelve months 2021 compared to 2020, Group
- Gross order intake amounted to SEK 6.6m (5.6), an increase of 18%
- Group net sales increased by 30% to SEK 6.5m (5.0)
- Loss for the period amounted to SEK -69.3m (-63.9)
- Earnings per share amounted to SEK -0.31 (-0.39)
Significant events during the fourth quarter
- Episurf Medical carried out a directed share issue of SEK 159m. Ilija Batljan entered as the largest shareholder
- Episurf Medical submitted 510(k) application for Episealer® Patellofemoral System
- Episurf Medical’s implants approved for sale in Saudi Arabia
- Episurf Medical hired Stephen Caswell to head Global Sales OUS
Significant events after the fourth quarter
- Episurf Medical’s implants approved for sale in Malaysia